Literature DB >> 16136508

Homeodomain proteins and eukaryotic translation initiation factor 4E (eIF4E): an unexpected relationship.

I Topisirovic1, K L B Borden.   

Abstract

The central role of post-transcriptional modification of the expression of several genes involved in tumorigenesis implicates eIF4E as a pivotal factor in the regulation of cell survival, growth and proliferation. Overexpression of eIF4E leads to malignant transformation in vitro and induces tumor formation in vivo. Furthermore, upregulated expression of eIF4E has been reported in a variety of human malignancies. Consequently, studies over the last ten years have sought to better characterize the molecular mechanisms and cellular factors that control eIF4E activity. These efforts have revealed a role for eIF4E in diverse biological processes including embryonic development, cell cycle progression, synaptic plasticity and cancer. In this review we focus on several members of the homeodomain protein family, which have recently been identified as a novel class of eIF4E regulators.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16136508     DOI: 10.14670/HH-20.1275

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  22 in total

1.  A look at life from the homeodomain. Workshop on homeodomain proteins, hematopoietic development and leukemias.

Authors:  Moisés Mallo; Maria Cristina Magli
Journal:  EMBO Rep       Date:  2006-09-15       Impact factor: 8.807

2.  Signaling with homeoprotein transcription factors in development and throughout adulthood.

Authors:  A Prochiantz
Journal:  Curr Genomics       Date:  2013-09       Impact factor: 2.236

Review 3.  Postnatal signalling with homeoprotein transcription factors.

Authors:  Alain Prochiantz; Julia Fuchs; Ariel A Di Nardo
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-09-26       Impact factor: 6.237

4.  Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.

Authors:  Filippa Pettersson; Christina Yau; Monica C Dobocan; Biljana Culjkovic-Kraljacic; Hélène Retrouvey; Hélène Retrouvay; Rachel Puckett; Ludmila M Flores; Ian E Krop; Caroline Rousseau; Eftihia Cocolakis; Katherine L B Borden; Christopher C Benz; Wilson H Miller
Journal:  Clin Cancer Res       Date:  2011-03-17       Impact factor: 12.531

5.  Structural insights into the allosteric effects of 4EBP1 on the eukaryotic translation initiation factor eIF4E.

Authors:  Nadeem Siddiqui; Wolfram Tempel; Lucy Nedyalkova; Laurent Volpon; Amy K Wernimont; Michael J Osborne; Hee-Won Park; Katherine L B Borden
Journal:  J Mol Biol       Date:  2011-12-09       Impact factor: 5.469

6.  Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults.

Authors:  Daniel Alvarez-Fischer; Julia Fuchs; François Castagner; Olivier Stettler; Olivia Massiani-Beaudoin; Kenneth L Moya; Colette Bouillot; Wolfgang H Oertel; Anne Lombès; Wolfgang Faigle; Rajiv L Joshi; Andreas Hartmann; Alain Prochiantz
Journal:  Nat Neurosci       Date:  2011-09-04       Impact factor: 24.884

Review 7.  Pondering the puzzle of PML (promyelocytic leukemia) nuclear bodies: can we fit the pieces together using an RNA regulon?

Authors:  Katherine L B Borden
Journal:  Biochim Biophys Acta       Date:  2008-06-18

8.  Chemical shift assignment of the viral protein genome-linked (VPg) from potato virus Y.

Authors:  Luciana Coutinho de Oliveira; Laurent Volpon; Michael J Osborne; Katherine L B Borden
Journal:  Biomol NMR Assign       Date:  2018-09-21       Impact factor: 0.746

9.  Cytoplasmic Prep1 interacts with 4EHP inhibiting Hoxb4 translation.

Authors:  J Carlos Villaescusa; Claudia Buratti; Dmitry Penkov; Lisa Mathiasen; Jesús Planagumà; Elisabetta Ferretti; Francesco Blasi
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

10.  Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.

Authors:  Biljana Culjkovic; Katherine L Borden
Journal:  J Oncol       Date:  2009-12-13       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.